Alpha Teknova (TKNO) Hisse Özeti
Alpha Teknova, Inc. Amerika Birleşik Devletleri'nde ve uluslararası alanda yeni tedavilerin, aşıların ve moleküler tanı yöntemlerinin keşfi, geliştirilmesi ve ticarileştirilmesi için kritik reaktifler üretmektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 2/6 |
| Gelecekteki Büyüme | 1/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 6/6 |
| Temettüler | 0/6 |
TKNO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
Read full narrativeAlpha Teknova, Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$3.83 |
| 52 Haftanın En Yüksek Seviyesi | US$7.36 |
| 52 Haftanın En Düşük Seviyesi | US$1.91 |
| Beta | 0.47 |
| 1 Aylık Değişim | 35.82% |
| 3 Aylık Değişim | 83.25% |
| 1 Yıllık Değişim | -45.75% |
| 3 Yıllık Değişim | 94.42% |
| 5 Yıllık Değişim | n/a |
| Halka arzdan bu yana değişim | -84.68% |
Son Haberler & Güncellemeler
Analyst Estimates: Here's What Brokers Think Of Alpha Teknova, Inc. (NASDAQ:TKNO) After Its First-Quarter Report
Alpha Teknova, Inc. ( NASDAQ:TKNO ) defied analyst predictions to release its quarterly results, which were ahead of...
TKNO: Long Term Revenue Guidance Will Support Future Upside Potential
Analysts have adjusted their price target on Alpha Teknova to $7.00 per share from $7.00, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. What's in the News Alpha Teknova issued revenue guidance for the fiscal year ending December 31, 2026, with an expected total revenue range of $42 million to $44 million (company guidance).TKNO: Long Term Revenue Guidance And Higher P/E Will Support Future Upside
Analysts have adjusted their price target on Alpha Teknova to $7.00 from $7.00, reflecting updated views on discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News Alpha Teknova issued revenue guidance for the fiscal year ending December 31, 2026, indicating an expected total revenue range of $42 million to $44 million.Recent updates
Analyst Estimates: Here's What Brokers Think Of Alpha Teknova, Inc. (NASDAQ:TKNO) After Its First-Quarter Report
Alpha Teknova, Inc. ( NASDAQ:TKNO ) defied analyst predictions to release its quarterly results, which were ahead of...TKNO: Long Term Revenue Guidance Will Support Future Upside Potential
Analysts have adjusted their price target on Alpha Teknova to $7.00 per share from $7.00, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. What's in the News Alpha Teknova issued revenue guidance for the fiscal year ending December 31, 2026, with an expected total revenue range of $42 million to $44 million (company guidance).TKNO: Long Term Revenue Guidance And Higher P/E Will Support Future Upside
Analysts have adjusted their price target on Alpha Teknova to $7.00 from $7.00, reflecting updated views on discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News Alpha Teknova issued revenue guidance for the fiscal year ending December 31, 2026, indicating an expected total revenue range of $42 million to $44 million.TKNO: Long Term Revenue Guidance Will Support Future Upside Potential
Analysts have adjusted their price target on Alpha Teknova to $7.00 from $7, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E that leave their fair value view essentially unchanged. What's in the News Alpha Teknova issued revenue guidance for the fiscal year ending December 31, 2026, indicating expected total revenue in a range of $42 million to $44 million.TKNO: Updated Revenue Outlook Will Support Future Upside Potential
Analysts have trimmed their price target on Alpha Teknova to $7.00 from $7 as they factor in updated assumptions for the discount rate, revenue growth, profit margin and future P/E. Their view remains broadly aligned with prior estimates while they fine tune the model inputs.TKNO: Steady Fair Value Anchor Will Support Future Upside Potential
Analysts have trimmed their price target on Alpha Teknova to $7.00 from $7 as they adjust assumptions around discount rates, revenue growth, profit margins, and future P/E. This reflects updated views on the company’s risk profile and earnings potential.TKNO: Steady Fair Value Anchor Will Support Future Upside Potential
Narrative Update on Alpha Teknova Analysts have kept their fair value estimate for Alpha Teknova broadly steady at about $7.00. They explain that modest tweaks to assumptions, such as a slightly higher discount rate, small adjustments to revenue growth and profit margin outlooks, and a marginally lower future P/E, leave their overall price target view essentially unchanged.TKNO: Earnings Guidance And Tuck In Deals Will Support Future Upside
Analysts have nudged their price target on Alpha Teknova slightly higher, citing updated assumptions around discount rates, revenue growth of about 17.6% and a future P/E near 46.1x to support a modestly refined fair value estimate of about $7.00 per share. What's in the News Alpha Teknova reiterated earnings guidance for the fiscal year ending December 31, 2025, with total revenue still expected in the range of $39 million to $42 million.Alpha Teknova, Inc.'s (NASDAQ:TKNO) Share Price Is Still Matching Investor Opinion Despite 29% Slump
Unfortunately for some shareholders, the Alpha Teknova, Inc. ( NASDAQ:TKNO ) share price has dived 29% in the last...TKNO: Earnings Guidance And Tuck In Deals Will Drive Future Upside
Analysts have modestly adjusted their price target on Alpha Teknova, citing an updated fair value of $7.00, a slightly higher discount rate, revised revenue growth expectations to 17.46%, a small change in the assumed profit margin, and a lower future P/E estimate of 46.25x. What's in the News Alpha Teknova reiterated earnings guidance for the fiscal year ending December 31, 2025, with expected total revenue in a range of $39 million to $42 million.TKNO: Earnings Guidance And Tuck In Deals Will Support Future Upside
Narrative Update: Alpha Teknova Analysts have modestly raised their price target on Alpha Teknova by approximately $1.00 per share, reflecting slightly higher assumptions for long term revenue growth and profit margins. This is partially offset by a marginally higher discount rate and a small reduction in projected future P E multiples.TKNO: Earnings Guidance And M&A Efforts Will Support Future Upside Potential
Analysts have trimmed their price target for Alpha Teknova from 8 dollars to 7 dollars, citing slightly slower expected revenue growth and a higher perceived discount rate, despite modestly better margin and valuation assumptions. What's in the News Reiterated 2025 earnings guidance, maintaining projected total revenue in the range of 39 million dollars to 42 million dollars for the year ending December 31, 2025 (company guidance).Earnings Update: Here's Why Analysts Just Lifted Their Alpha Teknova, Inc. (NASDAQ:TKNO) Price Target To US$10.00
Alpha Teknova, Inc. ( NASDAQ:TKNO ) just released its quarterly report and things are looking bullish. Results overall...Alpha Teknova, Inc.'s (NASDAQ:TKNO) P/S Is Still On The Mark Following 27% Share Price Bounce
Alpha Teknova, Inc. ( NASDAQ:TKNO ) shares have had a really impressive month, gaining 27% after a shaky period...Alpha Teknova, Inc.'s (NASDAQ:TKNO) 26% Cheaper Price Remains In Tune With Revenues
To the annoyance of some shareholders, Alpha Teknova, Inc. ( NASDAQ:TKNO ) shares are down a considerable 26% in the...Shareholders Will Probably Not Have Any Issues With Alpha Teknova, Inc.'s (NASDAQ:TKNO) CEO Compensation
Key Insights Alpha Teknova will host its Annual General Meeting on 17th of June CEO Stephen Gunstream's total...
Acquisitions And Collaborations Will Expand Cell And Gene Therapy Portfolio
Expansion through collaborations and acquisitions aims to boost top-line growth, margins, and financial stability amidst anticipated market rebound.Alpha Teknova, Inc. (NASDAQ:TKNO) Just Reported And Analysts Have Been Lifting Their Price Targets
Alpha Teknova, Inc. ( NASDAQ:TKNO ) shareholders are probably feeling a little disappointed, since its shares fell 9.3...Alpha Teknova, Inc. (NASDAQ:TKNO) Stocks Pounded By 31% But Not Lagging Industry On Growth Or Pricing
Alpha Teknova, Inc. ( NASDAQ:TKNO ) shareholders won't be pleased to see that the share price has had a very rough...Calculating The Fair Value Of Alpha Teknova, Inc. (NASDAQ:TKNO)
Key Insights The projected fair value for Alpha Teknova is US$8.71 based on 2 Stage Free Cash Flow to Equity With...Revenues Tell The Story For Alpha Teknova, Inc. (NASDAQ:TKNO) As Its Stock Soars 28%
Despite an already strong run, Alpha Teknova, Inc. ( NASDAQ:TKNO ) shares have been powering on, with a gain of 28% in...Revenues Tell The Story For Alpha Teknova, Inc. (NASDAQ:TKNO) As Its Stock Soars 42%
Despite an already strong run, Alpha Teknova, Inc. ( NASDAQ:TKNO ) shares have been powering on, with a gain of 42% in...Alpha Teknova, Inc. (NASDAQ:TKNO) Might Not Be As Mispriced As It Looks After Plunging 30%
Unfortunately for some shareholders, the Alpha Teknova, Inc. ( NASDAQ:TKNO ) share price has dived 30% in the last...Not Many Are Piling Into Alpha Teknova, Inc. (NASDAQ:TKNO) Stock Yet As It Plummets 25%
To the annoyance of some shareholders, Alpha Teknova, Inc. ( NASDAQ:TKNO ) shares are down a considerable 25% in the...Health Check: How Prudently Does Alpha Teknova (NASDAQ:TKNO) Use Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Some Analysts Just Cut Their Alpha Teknova, Inc. (NASDAQ:TKNO) Estimates
Market forces rained on the parade of Alpha Teknova, Inc. ( NASDAQ:TKNO ) shareholders today, when the analysts...Take Care Before Jumping Onto Alpha Teknova, Inc. (NASDAQ:TKNO) Even Though It's 30% Cheaper
Unfortunately for some shareholders, the Alpha Teknova, Inc. ( NASDAQ:TKNO ) share price has dived 30% in the last...Alpha Teknova, Inc. (NASDAQ:TKNO) Just Reported, And Analysts Assigned A US$23.00 Price Target
As you might know, Alpha Teknova, Inc. ( NASDAQ:TKNO ) just kicked off its latest quarterly results with some very...Hissedar Getirileri
| TKNO | US Life Sciences | US Pazar | |
|---|---|---|---|
| 7D | 6.7% | 1.9% | 2.2% |
| 1Y | -45.8% | 7.9% | 31.1% |
Getiri vs. Endüstri: TKNO geçen yıl % 7.9 oranında getiri sağlayan US Life Sciences sektörünün gerisinde kaldı.
Getiri vs Piyasa: TKNO geçen yıl % 31.1 oranında getiri sağlayan US Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| TKNO volatility | |
|---|---|
| TKNO Average Weekly Movement | 12.8% |
| Life Sciences Industry Average Movement | 8.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
İstikrarlı Hisse Senedi Fiyatı: TKNO hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: TKNO 'nin haftalık oynaklığı ( 13% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1996 | 158 | Stephen Gunstream | www.teknova.com |
Alpha Teknova, Inc. Amerika Birleşik Devletleri'nde ve uluslararası alanda yeni tedavilerin, aşıların ve moleküler teşhislerin keşfi, geliştirilmesi ve ticarileştirilmesi için kritik reaktifler üretmektedir. Şirketin başlıca ürünleri arasında hücre büyümesi ve klonlama için önceden dökülmüş ortam plakaları; sıvı mikrobiyal kültür ortamı ve hücresel genişleme için takviyeler; ve numune manipülasyonu, yeniden süspansiyon ve saflaştırma için moleküler biyoloji reaktifleri bulunmaktadır. Biyolojik araştırma ve ilaç keşfinde kullanılmak üzere kimyasal formülasyonlar sağlayan laboratuvar temelleri ve protein terapileri, gen terapileri, mRNA aşıları ve teşhis kitlerinin geliştirilmesi ve üretiminde kullanılan özel bir ürün olan klinik çözümler sunmaktadır.
Alpha Teknova, Inc. Temel Bilgiler Özeti
| TKNO temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$205.34m |
| Kazançlar(TTM) | -US$17.17m |
| Gelir(TTM) | US$41.80m |
TKNO aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| TKNO gelir tablosu (TTM) | |
|---|---|
| Gelir | US$41.80m |
| Gelir Maliyeti | US$27.58m |
| Brüt Kâr | US$14.22m |
| Diğer Giderler | US$31.39m |
| Kazançlar | -US$17.17m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -0.32 |
| Brüt Marj | 34.01% |
| Net Kâr Marjı | -41.07% |
| Borç/Özkaynak Oranı | 20.3% |
TKNO uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/11 13:38 |
| Gün Sonu Hisse Fiyatı | 2026/05/08 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Alpha Teknova, Inc. 7 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Mark Massaro | BTIG |
| Matthew Hewitt | Craig-Hallum Capital Group LLC |
| Paul Knight | KeyBanc Capital Markets Inc. |